The third domestically produced adalimumab Surixin® pricing is released for the first time in the charity donation policy

October 10, according to Sina Pharmaceuticals' latest certification, Thyda Bio's third domestic Adamu single resistance (Su Lixin®) price announced - the market price of 1150 yuan / bottle.
At the same time, Surixin®'s drug-giving policy was made public for the first time: Xinda Bio will provide 12,000 Sulixins ® for the aid program, low-income patients can enjoy the purchase of 4 give-away 2 free of charge 6 Sulixin ®.
Su Lixin® officially listed in September this year, approved adaptive disorders for the treatment of rheumatoid arthritis, strong straight spina bifida and psoriasis, after the two domestic Adamo single anti-bio-similar drugs on the market, respectively, on November 7, 2019, The Glili ®; On December 6, 2019, Haizheng Pharmaceuticals listed an ®.
Adamu single antigen research drug (Shumeile®) developed by AbbVie, in 2002 for the first time by the United States FDA approval, in Europe and the United States has been approved rheumatoid arthritis, strong straight spina bifida, psoriasis arthritis, Early iditable arthritis, Crohn's disease, ulcerative colitis, purulent sweat adenitis, vineitis and more than 10 kinds of adaptive disorders, since 2012, Shumeile ® has been the world's top prescription drug sales, known as the "king of drugs."
february 2010, the ® was approved in China, but for many years its market penetration in China was not high and sales were flat.
statistics, in 2018, the sales of ® China did not reach 400 million yuan, accounting for about 0.2% of global sales, drug penetration rate is lower than the global average.
generally believe that this has something to do with its high prices and the low number of approved adaptive disorders.
To present, only 6 adaptations have been approved in China, including rheumatoid arthritis, strong straightening spina bifidosis, psoriasis, multi-joint type of young idynetic arthritis (2019.11), moderate-severe active Crohn's disease® (2020.1.8), and glucitis (2020.3).
Since 2019, the country has announced a reduction in the price of Shumeile ®, initially from 7,600 yuan to 3,160 yuan, a drop of nearly 60 percent, the industry agreed that Shumeile® this move is to pave the way for access to health insurance.
, and in 2019, AbbVie's Shumeile ® was included in the National Health Insurance List, which pays $1,290 a day.
addition, in the first two years, the core patents of ®'s core patents expired in China, and many Chinese companies began to attack the market ® mele.
B.Ottay's Gree Li® is priced at 1,160 yuan/branch (according to the Medical Rubik's Cube monitoring, in Qinghai Province and Zhejiang Province, Hunan Province tender has been reduced to® 1150 yuan); Xinda Bio's Su Lixin ® today announced that the market price is also 1150 yuan / bottle, are slightly lower than the ® health insurance payment standard is 1290 yuan / branch.
the present point of view, has formed a three-legged three-legged Adamu single resistance price did not open the gap, will certainly be commercial sales and expand the adaptive aspects of a fierce market competition.
In addition, it is worth noting that Fuhong Hanxuan, united organisms, Zhengda Tianqing this variety is also on the way to the market, and Fuhong Hanxuan's variety has been included in the priority review sequence, approved for listing also refers to the day to come.
.